Fusion Antibodies (FAB) Competitors

hVIVO currently has a consensus target price of GBX 15, indicating a potential upside of 115.52%. Given hVIVO's stronger consensus rating and higher possible upside, equities analysts clearly believe hVIVO is more favorable than Fusion Antibodies.

11.8% of hVIVO shares are held by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are held by institutional investors. 4.9% of hVIVO shares are held by insiders. Comparatively, 5.9% of Fusion Antibodies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, hVIVO's average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score.

hVIVO has a net margin of -12.48% compared to Fusion Antibodies' net margin of -91.92%. hVIVO's return on equity of -14.65% beat Fusion Antibodies' return on equity.

hVIVO has a beta of 1.707, suggesting that its stock price is 71% more volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.224, suggesting that its stock price is 22% more volatile than the broader market.

hVIVO has higher revenue and earnings than Fusion Antibodies. hVIVO is trading at a lower price-to-earnings ratio than Fusion Antibodies, indicating that it is currently the more affordable of the two stocks.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Fusion Antibodies' return on equity of -210.32% beat Hemogenyx Pharmaceuticals' return on equity.

Fusion Antibodies has a beta of 1.224, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

7.6% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 5.9% of Fusion Antibodies shares are owned by company insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Fusion Antibodies has a beta of 1.224, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, indicating that its stock price is 95% less volatile than the broader market.

Fusion Antibodies has a net margin of -91.92% compared to Roquefort Therapeutics' net margin of -57,057.07%. Roquefort Therapeutics' return on equity of -18.71% beat Fusion Antibodies' return on equity.

Roquefort Therapeutics has lower revenue, but higher earnings than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

7.6% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 2.1% of Roquefort Therapeutics shares are owned by institutional investors. 5.9% of Fusion Antibodies shares are owned by insiders. Comparatively, 36.1% of Roquefort Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

7.6% of Fusion Antibodies shares are held by institutional investors. Comparatively, 1.5% of Poolbeg Pharma shares are held by institutional investors. 5.9% of Fusion Antibodies shares are held by insiders. Comparatively, 7.5% of Poolbeg Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Fusion Antibodies has a beta of 1.224, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Poolbeg Pharma has a beta of 1.812, indicating that its stock price is 81% more volatile than the broader market.

In the previous week, Poolbeg Pharma had 1 more articles in the media than Fusion Antibodies. MarketBeat recorded 1 mentions for Poolbeg Pharma and 0 mentions for Fusion Antibodies. Fusion Antibodies' average media sentiment score of 0.00 equaled Poolbeg Pharma'saverage media sentiment score.

Fusion Antibodies has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Fusion Antibodies, indicating that it is currently the more affordable of the two stocks.

Poolbeg Pharma has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Poolbeg Pharma's return on equity of -55.47% beat Fusion Antibodies' return on equity.